Merck said Lynparza (olaparib), a targeted therapy co-developed with AstraZeneca, has become the first PARP inhibitor approved by the Food and Drug Administration for treating metastatic breast cancer.

In a collaboratively funded government effort advancing treatments for the Zika virus, scientists recently announced that an exploratory version of the Zika purified inactivated virus (ZPIV) proved safe, tolerated and effective in national study participants.

GlaxoSmithKline plc recently received Food and Drug Administration (FDA) approval for Nucala (mepolizumab) to target a form of vasculitis called eosinophilic granulomatosis with polyangiitis (EGPA).

Eli Lilly and Co. recently embarked on a feasibility study to assess its Connected Diabetes Ecosystem’s automated insulin delivery (AID) treatment for patients with Type 1 diabetes.

Amgen recently attained approval from the Food and Drug Administration (FDA) for Repatha following a priority review of the company’s supplemental biologics license application.

The National Institutes of Health (NIH) recently launched a clinical trial for an experimental vaccine that aims prevent HIV infection.

While multibillion-dollar mega-mergers at the top of the end of the health-sector chain garner headlines and potential regulatory scrutiny, hospital group consolidations are also concerning experts who believe they may not produce better care and lower costs.

Details of a $69 billion deal in which pharmacy giant CVS would take over health insurer Aetna emerged in multiple reports Sunday.

Novartis has had received positive topline results from its global MONALEESA-7 trial of Kisqali for metastatic breast cancer, the company announced in a press release.

EMD Serono, Merck KGaA’s U.S. and Canada-based biopharmaceutical business, recently received Food and Drug Administration approval for a redesigned version of a pen injector, designed to be used to induce ovulation and pregnancy in certain oligo-anovulatory women.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion of AstraZeneca's and MedImmune's benralizumab, which is designed to treat adults with severe eosinophilic asthma.

Abbott has received approval from Japan’s Ministry of Health, Labor and Welfare for the company’s MitraClip, making it the first minimally invasive device to treat people in Japan with mitral regurgitation (MR) heart disease.

The Centers for Disease Control and Prevention (CDC) recently formed a five-year cooperative agreement with the American Diabetes Association (ADA) to expand the National Diabetes Prevention Program (National DPP) in underserved, primarily rural areas.

Novartis recently submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for what it calls a novel immunocellular therapy and one-time treatment that utilizes a patient’s own T cells to fight cancer.

Opdivo, a medication effective for certain forms of high-risk skin cancer, has earned approval from the European Medicines Agency for expanded use in patients with advanced melanoma who have had tumors surgically removed, Bristol-Myers Squibb, the drug's manufacturer, said in a release.

The U.S. Food and Drug Administration (FDA) recently granted fast track designation to Astellas Pharma to develop gilteritinib, an investigational compound, for patients with FLT3 mutation-positive (FLT3+) relapsed or refractory acute myeloid leukemia (AML).

The U.S. Food and Drug Administration agreed to review Amgen’s supplemental biologics license application for Prolia (denosumab), a drug targeting patients with glucocorticoid-induced osteoporosis (GIOP), an Amgen release said.

The future of Wisconsin's $750,000 cap on noneconomic damages is up to the state's Supreme Court, the American Medical Association reported.

The question of whether a specific vitamin regimen can be trademarked was settled recently when Eli Lilly successfully retained its right to patent an injectable non-small cell lung cancer treatment called Alimta (pemetrexed).

Bristol-Myers Squibb said its Opdivo (nivolumab) treatment recently became the first to obtain U.S. Food and Drug Administration (FDA) approval for certain types of cancer patients whose illness proved unresponsive to prior regimens.